ARDX news

Latest 3 stories · newest Nov 3, 2026

ARDX

Ardelyx Reports Q3 Financial With IBSRELA Revenue Growth

Ardelyx reported third-quarter product revenue of $125.5 million, driven by 23% growth in its IBSRELA franchise. The biopharmaceutical company also announced full-year guidance and provided updates on its Phase 3 ACCEL trial.

Earnings|Guidance|Other Nov 3, 2026 sentiment +0.70 SEC filing ↗

ARDX

Arcadia Announces 2026 Omnibus Equity Incentive Plan

Arcadia Biosciences, Inc. filed a form 8-K to issue Exhibit 10.1, establishing a new 2026 Omnibus Equity Incentive Plan for employee compensation.

Regulatory Sep 15, 2026 sentiment 0.00 SEC filing ↗

ARDX

Ardelyx increases equity plan share reserve by 9M shares to 77.5M total

Ardelyx's board approved a second amendment to its 2014 equity plan, increasing the maximum shares available for awards by 9 million to provide flexibility in employee compensation and retention. The amendment requires stockholder approval within 12 months and is intended to support the company's ab…

Other Jun 17, 2026 sentiment 0.00 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same ARDX feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/ARDX/newsSTART FREE